Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
Avita Medical Inc (RCEL) delivers breakthrough regenerative medicine solutions through its FDA-approved RECELL system, transforming wound care and skin restoration. This news hub provides investors and medical professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative information about RCEL's innovative approach to burn treatment and skin repair, including FDA clearances, international regulatory progress, and partnerships shaping the future of point-of-care cell therapy. Our curated collection features press releases on product innovations, peer-reviewed research validations, and market expansion activities.
Key content categories include clinical trial outcomes, regulatory submissions, financial performance updates, and technological refinements to the RECELL platform. Users benefit from centralized access to verified information supporting informed analysis of this medical device innovator.
Bookmark this page for streamlined tracking of Avita Medical's progress in advancing regenerative wound care solutions. Check regularly for updates demonstrating how RCEL's patented technology continues to redefine standards in acute burn treatment and complex wound management.
AVITA Medical (NASDAQ: RCEL) has received FDA approval for RECELL GO mini, a new disposable cartridge designed for treating smaller wounds up to 480 square centimeters, compared to the standard RECELL GO's 1,920 square centimeters capacity. The device, part of the RECELL GO platform, uses the same multi-use processing device but features a modified cartridge optimized for smaller skin samples, reducing resource use and minimizing waste.
This approval addresses a critical need in the full-thickness skin defect market, particularly targeting high-volume smaller wounds. The company plans to begin rollout in trauma and burn centers during Q1 2025, aiming to provide an entry point for clinicians who may not have previously used the RECELL GO platform for smaller wounds.
AVITA Medical (NASDAQ: RCEL) has received FDA 510(k) clearance for Cohealyx, a collagen-based dermal matrix co-developed with Regenity Biosciences. The product is designed for tissue integration and revascularization in full-thickness wound treatment. Preclinical studies showed Cohealyx generated robust tissue supporting skin grafts faster than leading competitors.
This strategic addition complements AVITA's existing RECELL and PermeaDerm portfolio, expected to triple the company's addressable market in burns. The company plans to initiate clinical studies in early 2025 and launch full commercialization efforts in Q2 2025.
AVITA Medical (NASDAQ: RCEL), a regenerative medicine company specializing in wound care management and skin restoration devices, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Jim Corbett will deliver a presentation on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. The presentation will be available via live audio webcast on the company's investor relations website, with a replay option available after the event concludes.
AVITA Medical (NASDAQ: RCEL) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. CEO Jim Corbett will deliver a presentation on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time. The company, which specializes in regenerative medicine and first-in-class devices for wound care management and skin restoration, will provide a live webcast of the fireside chat through their investor relations website. The presentation will remain available for replay after the event concludes.
AVITA Medical (NASDAQ: RCEL) has signed an exclusive distribution agreement with Revolution Surgical Pty to expand into the Australian and New Zealand markets. The agreement covers the distribution of the RECELL® product platform, including RECELL GO® (pending regulatory approval). This strategic partnership represents RECELL's return to Australia, where the technology was originally developed, and aims to enhance product availability and accessibility in these regions.
AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for November 12, 2024, at 2:00 p.m. PST. The presentation will be led by CEO Jim Corbett and CFO David O'Toole, covering financial and business results from their recent third-quarter 2024 earnings webcast. The event will include a Q&A session, with participants able to submit questions through the registration page. The webinar will be available for replay on the company's investor relations website after the presentation.
AVITA Medical (NASDAQ: RCEL) reported strong Q3 2024 results with commercial revenue of $19.5 million, up 44% year-over-year. The company achieved a gross profit margin of 83.7%. Key developments include a distribution agreement with Regenity Biosciences for Cohealyx™ and an amended credit agreement with OrbiMed. The company expects Q4 2024 revenue between $22.3-24.3 million and maintains full-year guidance of $68.0-70.0 million. However, net loss widened to $16.2 million ($0.62 per share) compared to $8.7 million ($0.34 per share) in Q3 2023, with operating expenses increasing to $30.2 million.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company specializing in wound care management and skin restoration devices, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time on the same day (8:30 a.m. AEDT on November 8, 2024) to discuss the results and recent business highlights.
Investors can access the live webcast through the Events & Presentations section of AVITA Medical's website. For telephone participation, pre-registration is required. A replay of the webcast will be available on the Investor Relations website shortly after the event.
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leader in regenerative medicine and wound care management, has announced its participation in the 2024 Cantor Global Healthcare Conference. David O'Toole, the company's Chief Financial Officer, will present on Wednesday, September 18, 2024, at 9:10 a.m. Eastern Time.
Investors and interested parties can access a live webcast of the presentation through the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com. For those unable to attend the live event, a replay of the webcast will be made available following the conclusion of the conference.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leader in regenerative medicine and wound care management, has announced its participation in the 8th Annual Best Ideas Growth (BIG8) Conference organized by Lake Street Capital Markets. The event is scheduled for September 12, 2024, in New York.
CEO Jim Corbett will be present to conduct one-on-one meetings with institutional investors throughout the day. This conference provides AVITA Medical with an opportunity to showcase its first-in-class devices for wound care and skin restoration to potential investors.
Interested parties are encouraged to contact their Lake Street representative for more information or to schedule a meeting with AVITA Medical's management team.
FAQ
What is the current stock price of Avita Medical (RCEL)?
What is the market cap of Avita Medical (RCEL)?
